{"Clinical Trial ID": "NCT02187744", "Intervention": ["INTERVENTION 1:", "- FP-05280014", "Participants received a loading dose of 8 mg/kg PF-05280014 on the first day of cycle 1. Subsequent infusions followed every 3 weeks with a dose of 6 mg/kg.", "INTERVENTION 2:", "- Trastuzumab-EU", "Participants received a loading dose of 8 mg/kg trastuzumab-EU on the first day of cycle 1. Subsequent infusions followed every 3 weeks with a dose of 6 mg/kg."], "Eligibility": ["Incorporation criteria:", "HER2 has historically confirmed an overexpression of invasive breast cancer.", "A plan for a definitive surgical resection of the breast tumour (i.e., lumpectomy or mastectomy, and sentinel ganglia biopsy (SN) or dissection of axillary lymph nodes (ALND).", "A plan for neoadjuvant chemotherapy.", "A disease measurable in the breast after diagnostic biopsy, defined as the longest diameter 2.0 cm.", "- Exclusion criteria:", "A bilateral breast cancer.", "Inflammatory breast cancer.", "Presence of known distant metastases.", "Has received prior treatment, including chemotherapy, endocrine therapy, biological therapy, radiotherapy or surgery, except for the diagnostic biopsy of primary breast cancer."], "Results": ["Performance measures:", "Percentage of participants with Ctrough concentration (Cycle 6 before dose) at steady state > 20 \u03bcg/mL at cycle 5.", "The percentage of participants with a cycle 5 Ctrough (Cycle 6 pre-dose) > 20 \u03bcg/mL in each treatment group, the denominator being the number of participants in the population per protocol for each treatment group.", "Calendar: Cycle 5", "Results 1:", "Title of arm/group: PF-05280014", "Description of the arm/group: Participants received a loading dose of 8 mg/kg PF-05280014 on the first day of cycle 1. Subsequent infusions followed every 3 weeks with a dose of 6 mg/kg.", "Total number of participants analysed: 101", "Type of measurement: Number", "Unit of measure: percentage of participants 92.1 (between 85.0 and 96.5)", "Results 2:", "Title of the arm/group: Trastuzumab-EU", "Description of the arm/group: Participants received a loading dose of 8 mg/kg trastuzumab-EU on the first day of cycle 1. Subsequent infusions followed every 3 weeks with a dose of 6 mg/kg.", "Total number of participants analysed: 89", "Type of measurement: Number", "Unit of measure: Percentage of participants 93.3 (85.9 to 97.5)"], "Adverse Events": ["Undesirable Events 1:", "Total: 7/113 (6.19 per cent)", "Febrile neutropenia 1/113 (0.88%)", "Neutropenia 1/113 (0.88%)", "Anemia 0/113 (0.00 %)", "Pancytopenia 1/113 (0.88%)", "Proctitis 1/113 (0.88%)", "1/113 (0.88%)", "Gastrointestinal infection 0/113 (0.00 %)", "Abscesses from injection site 1/113 (0.88%)", "- Tooth infection 0/113 (0.00 %)", "- Hip fracture 0/113 (0.00 %)", "Increased blood creatinine 1/113 (0.88%)", "Adverse Events 2:", "Total: 6/112 (5.36 per cent)", "Febrile neutropenia 2/112 (1.79 %)", "Neutropenia 1/112 (0.89%)", "Anemia 1/112 (0.89%)", "Pancytopenia 0.112 (0.00 %)", "Proctitis 0/112 (0.00 %)", "0/112 (0.00 %)", "gastrointestinal infection 1/112 (0.89%)", "Abscesses from injection site 0/112 (0.00 %)", "- Teeth infection 1/112 (0.89%)", "- Hip fracture 1/112 (0.89%)", "Blood creatinine increased 0.112 (0.00 %)"]}